CTOs on the Move

Osco Drug

www.oscodrug.com

 
Osco Drug is a Springfield, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.oscodrug.com
  • 1901 W Monroe St
    Springfield, IL USA 62704
  • Phone: 217.787.2830

Executives

Name Title Contact Details

Similar Companies

Vifor Pharma

Vifor Pharma is a Basking Ridge, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Elixir

Elixir, (formerly EnvisionRxOptions) a wholly owned subsidiary of Rite Aid, is a pharmacy benefits and services company with the unique ability to optimize the full pharmacy care experience.

MIND 24-7

MIND 24-7 is fundamentally changing the landscape of accessible behavioral health by offering walk-in urgent mental health and substance abuse services such as Psych Express Care, Psych Crisis Care, and Psych Progressions. MIND 24-7 fills the gap for those seeking help by being available right when they need it – 24 hours a day, 365 days a year. Using innovations in value-based care models to improve and expand access to care, MIND 24-7 not only enhances quality patient care, but reduces pressure on the system, reducing costly emergency room visits, in-patient treatment, and readmissions for crisis care.

Atmos-Tech Industries

Atmos- Tech Industries offers high quality controlled environment and cleanroom products and superior customer service.

Everest Medicines

Everest Medicines is dedicated to its mission of developing and commercializing novel transformative pharmaceutical therapies for patients in mainland China and other Asian territories. We strive to be the partner of choice for innovative companies around the world with products that address critical unmet medical needs for patients in Greater China and have a high probability of market approval. The Everest Medicines team has deep expertise and extensive track record of high quality clinical development, regulatory affairs, CMC, business development and operations both in China and with leading global pharmaceutical companies. The company`s Series A round was led by C-Bridge Capital, a top-tier China healthcare private equity firm, with US $800 million under management.